分组1 - Keros Therapeutics reported quarterly earnings of $3.62 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.01 per share, and showing an improvement from a loss of $1.21 per share a year ago, resulting in an earnings surprise of 36,300% [1] - The company posted revenues of $211.25 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 149.64%, compared to revenues of $0.08 million in the same quarter last year [2] - Keros Therapeutics shares have declined approximately 8.1% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$1.02 on revenues of $8.28 million, and for the current fiscal year, it is -$3.46 on revenues of $100.68 million [7] - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

CuriosityStream Inc. (CURI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced a loss of $0.05, delivering a surprise of -150%.Over the last four quarters, the comp ...

While Clover Health Investments has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Clover Health Investments, Corp. (CLOV) came out with quarterly ear ...

ProAssurance (PRA) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -31.58%. A quarter ago, it was expected that this medical professional liability insurer would post earnings of $0.15 per share when it actually produced earnings of $0.36, delivering a surprise of 140%.Over the last f ...

Core Viewpoint - Cirrus Logic reported strong quarterly earnings, significantly exceeding expectations, indicating robust performance in the semiconductor industry [1][2]. Financial Performance - The company achieved earnings of $1.67 per share, surpassing the Zacks Consensus Estimate of $1.15 per share, and up from $1.24 per share a year ago, representing a 45.22% earnings surprise [1] - Revenues for the quarter reached $424.46 million, exceeding the Zacks Consensus Estimate by 11.70%, and up from $371.83 million year-over-year [2] - Over the last four quarters, Cirrus Logic has consistently surpassed consensus EPS and revenue estimates [2] Market Performance - Cirrus Logic shares have declined approximately 1.1% year-to-date, while the S&P 500 has decreased by 3.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - Current consensus EPS estimate for the upcoming quarter is $0.83 on revenues of $341.24 million, and for the current fiscal year, it is $6.82 on revenues of $1.87 billion [7] - The outlook for the semiconductor industry is positive, with the Electronics - Semiconductors sector ranking in the top 35% of Zacks industries, suggesting potential for outperformance [8] Industry Context - Marvell Technology, another player in the semiconductor industry, is expected to report earnings of $0.61 per share, reflecting a year-over-year increase of 154.2%, with revenues projected at $1.88 billion, up 61.6% from the previous year [9][10]

Company Performance - Heron Therapeutics reported quarterly earnings of $0.01 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share, and improving from a loss of $0.02 per share a year ago, representing an earnings surprise of 200% [1] - The company posted revenues of $38.9 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.93%, compared to revenues of $34.67 million in the same quarter last year [2] - Over the last four quarters, Heron Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Heron Therapeutics shares have increased by approximately 39.2% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $37.68 million, and for the current fiscal year, it is $0.01 on revenues of $157.15 million [7] Industry Outlook - The Medical - Drugs industry, to which Heron Therapeutics belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]

Global Payments (GPN) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.83%. A quarter ago, it was expected that this electronics payment processing company would post earnings of $2.96 per share when it actually produced earnings of $2.95, delivering a surprise of -0.34%.Over the las ...

Madison Square Garden Entertainment (MSGE) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also ho ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.71%. A quarter ago, it was expected that this company would post a loss of $1.10 per share when it actually produced a loss of $1.09, delivering a surprise of 0.91%.Over the last four quarters, the company has s ...

DoorDash, Inc. (DASH) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that this company would post earnings of $0.34 per share when it actually produced earnings of $0.33, delivering a surprise of -2.94%.Over the last four quarters, the company has surp ...